These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9220308)

  • 1. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
    Dorszewski A; Göhmann E; Dorsźewski B; Werner GS; Kreuzer H; Figulla HR
    J Card Fail; 1997 Jun; 3(2):91-6. PubMed ID: 9220308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
    Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
    J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
    Cohn JN; Ziesche S; Smith R; Anand I; Dunkman WB; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L
    Circulation; 1997 Aug; 96(3):856-63. PubMed ID: 9264493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
    de Vries RJ; Queré M; Lok DJ; Sijbring P; Bucx JJ; van Veldhuisen DJ; Dunselman PH
    Am J Cardiol; 1995 Dec; 76(17):1253-8. PubMed ID: 7503006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
    Dickstein K; Chang P; Willenheimer R; Haunsø S; Remes J; Hall C; Kjekshus J
    J Am Coll Cardiol; 1995 Aug; 26(2):438-45. PubMed ID: 7608448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
    Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.
    Dunselman PH;
    Int J Cardiol; 2001 Feb; 77(2-3):131-8; discussion 139-40. PubMed ID: 11182175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.
    Giles TD; Katz R; Sullivan JM; Wolfson P; Haugland M; Kirlin P; Powers E; Rich S; Hackshaw B; Chiaramida A
    J Am Coll Cardiol; 1989 May; 13(6):1240-7. PubMed ID: 2539403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
    Packer M; Gheorghiade M; Young JB; Costantini PJ; Adams KF; Cody RJ; Smith LK; Van Voorhees L; Gourley LA; Jolly MK
    N Engl J Med; 1993 Jul; 329(1):1-7. PubMed ID: 8505940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
    van den Broek SA; de Graeff PA; van Veldhuisen DJ; van Gilst WH; Hillege H; Wesseling H; Lie KI
    J Card Fail; 1997 Sep; 3(3):165-71. PubMed ID: 9330124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor.
    Giles TD; Fisher MB; Rush JE
    Am J Med; 1988 Sep; 85(3B):44-7. PubMed ID: 2844087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
    van Wijngaarden J; Smit AJ; de Graeff PA; van Gilst WH; van der Broek SA; van Veldhuisen DJ; Lie KI; Wesseling H
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):240-5. PubMed ID: 7511753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
    Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.